Celeris Therapeutics, founded in Graz, Austria, is an AI-powered company dedicated to accelerating drug discovery through deep learning and lab automation. Their core mission is to address the challenge of "undruggable" proteins, which constitute 80% of disease-causing proteins that current technologies cannot target. By leveraging their proprietary platform for the prospective design of molecular glue degraders, Celeris Therapeutics aims to develop treatments for a wide range of incurable diseases, significantly impacting the healthcare market.

Notable figures affiliated with Celeris Therapeutics include experts in AI, drug discovery, and molecular biology, though specific names are not provided. The company has garnered attention for its innovative approach and has likely attracted investment from forward-thinking venture capitalists interested in biotech and AI. Key achievements include the development of their AI-enabled platform, which has the potential to revolutionize the way new drugs are discovered and developed. Overall, Celeris Therapeutics is making significant strides in transforming drug discovery, offering hope for treatments of previously untreatable conditions.